BTH1677 in combination with cetuximab with and without irinotecan in patients with advanced metastatic colorectal cancer
| Autor: | J.F. Marier, Janet B Bautista, Myra L. Patchen, Michele Gargano, Richard Walsh, Paulo S Tioleco, Myra L Flores, Gerardo H Cornelio, Maria E Tamayo, Martin Beliveau, Michael R Kurman |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Subset Analysis Oncology medicine.medical_specialty Colorectal cancer medicine.disease_cause 03 medical and health sciences 0302 clinical medicine Pharmacokinetics Internal medicine medicine In patient Adverse effect neoplasms Cetuximab business.industry Gastroenterology medicine.disease digestive system diseases Irinotecan 030104 developmental biology 030220 oncology & carcinogenesis KRAS business medicine.drug |
| Zdroj: | Colorectal Cancer. 5:95-108 |
| ISSN: | 1758-1958 1758-194X |
| Popis: | Aim: Investigate the safety, pharmacokinetics (PK) and efficacy of BTH1677/cetuximab, with and without irinotecan, in patients with metastatic colorectal cancer (mCRC). Patients & methods: Patients with recurrent or progressive mCRC were assigned to BTH1677/cetuximab/irinotecan (group 1; n = 10) or BTH1677/cetuximab (group 2; n = 22). Adverse events, PK parameters and tumor response were assessed. Results & conclusion: Adverse events were consistent with those expected of the backbone therapy of cetuximab/irinotecan (group 1) or cetuximab alone (group 2). The BTH1677 PK profiles were similar in the two groups. The overall response rates were 30.0% (group 1) and 22.7% (group 2); in KRAS wild-type subset analysis, rates were 42.9% and 45.5%, respectively. BTH1677 therapy was tolerable and warrants further evaluation for treatment of mCRC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|